Exclusive: Horizon CEO Tim Walbert talks M&A, FTC post-Amgen deal close

For 10 months, the bio­phar­ma in­dus­try wait­ed to see if Am­gen and Hori­zon Ther­a­peu­tics would pre­vail in their $27.8 bil­lion merg­er fol­low­ing scruti­ny and chal­lenges from the FTC and oth­er gov­ern­ment lead­ers.

Last Fri­day, the decades-old Cal­i­for­nia drug­mak­er closed its ac­qui­si­tion of the Dublin and Chica­go-area biotech, bring­ing a slate of rare dis­ease med­ica­tions in­to its port­fo­lio on the promise that Am­gen wouldn’t bun­dle its med­i­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.